{"organizations": [], "uuid": "1eb0b218111a7c08e9f3c97a8021f79af678c26c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-novartis-zessly/novartis-receives-eu-approval-for-biosimilar-zessly-idINKCN1IP0P2", "country": "US", "domain_rank": 408, "title": "Novartis receives EU approval for biosimilar Zessly", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-24T08:43:00.000+03:00", "replies_count": 0, "uuid": "1eb0b218111a7c08e9f3c97a8021f79af678c26c"}, "author": "", "url": "https://in.reuters.com/article/us-novartis-zessly/novartis-receives-eu-approval-for-biosimilar-zessly-idINKCN1IP0P2", "ord_in_thread": 0, "title": "Novartis receives EU approval for biosimilar Zessly", "locations": [], "entities": {"persons": [{"name": "crohn", "sentiment": "none"}, {"name": "brenna hughes neghaiwi", "sentiment": "none"}, {"name": "silke koltrowitz", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "eu", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "sandoz", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "european commission", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 24, 2018 / 5:46 AM / Updated 15 hours ago Novartis receives EU approval for biosimilar Zessly Reuters Staff 1 Min Read\nZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases.\nZessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohnâ€™s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis, Novartis said in a statement on Thursday.\nZessly is the sixth approved biosimilar medicine for Sandoz, with several more major oncology and immunology launches expected globally by 2020, Novartis said. Reporting by Silke Koltrowitz; editing by Brenna Hughes Neghaiwi", "external_links": [], "published": "2018-05-24T08:43:00.000+03:00", "crawled": "2018-05-24T09:25:35.004+03:00", "highlightTitle": ""}